About Us

Our Mission

  • Improve health outcomes by increasing the quality and availability of difficult-to-procure transfusable blood products
  • Create an emotional connection between donors and our shared mission to save lives
  • Foster an enduring relationship with our hospital customers and provide them an unprecedented level of service quality
  • Serve as a leader in the efforts to modernize and stabilize the blood industry, creating pertinent safeguards in times of supply chain disruption

Our Process

We build

and operate commercial blood collection centers across the US that meet all federal, state, local, AABB, and CLIA standards

We maintain

a pedigreed donor pool through strict adherence to the AABB standards and the use of key predictors of collections efficiencies

We produce

100% pathogen reduced single donor apheresis platelets (PR-SDPs)

We believe

the use of a responsibly compensated donor model is necessary to meet the structurally growing demand for platelets needed for patients

We connect

our donors to the vital role they play in the mission to improve the availability of blood products for patients in their local community

We value

the non-profit blood banking community and the critical role it plays in sustaining the nation’s blood supply

Our Team

Board of Directors

Laurence Cooper, MD PhDCEO, Ziopharm Oncology, Inc.

Vijai Mohan Founder and CEO, STS

Carol MooreSVP of Regulatory and Quality, Cerus Corporation

George “Bud” Scholl – CEO OneBlood, Inc.

Senior Advisors

Andrew Heaton, MBBS Former Chief Medical Officer, Novartis Diagnostics

John Roback, MD PhDDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine

Susan Shurin, MDFormer Deputy Director of National Heart, Lung, and Blood Institute

Our Partners

OneBlood is the third-largest non-profit blood collection organization in the US and is responsible for distributing over one million products annually to 260 hospital partners.
The Cerus INTERCEPT blood system is the only FDA cleared pathogen reduction workflow. INTERCEPT inactivates a range of pathogenic organisms in transfusable blood components. 

Our Affiliations

STS is a member of both the American Association of Blood Banks (AABB) and the Plasma Protein Therapeutics Association (PPTA)